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Response to azacitidine is independent of p53
expression in higher-risk myelodysplastic syndromes
and secondary acute myeloid leukemia
The demethylating agent azacitidine (AZA) is currently
the standard of care for patients with higher-risk myelodys-
plastic syndromes (MDS) not eligible for allogeneic stem
cell transplant (HSCT). Although approximately 50% of
patients show a response to AZA it is not currently possible
to accurately predict which patients will respond. In addi-
tion, higher-risk MDS frequently progress to secondary
acute myeloid leukemia (sAML) within months, even in the
presence of continuous therapy with AZA. Somatic gene
mutations affecting prognosis have recently been identified
in MDS.1-4 Among these, mutations in TP53, EZH2, ETV6,
RUNX1 and ASXL1 are associated with poor overall sur-
vival.1-4 TP53 mutations are mainly seen in high-risk MDS
with abnormal chromosome 5 or complex karyotype.5,6 In
particular, TP53 mutations have been shown to confer
resistance to lenalidomide in MDS with del(5q).7 In a recent
publication by Saft et al., p53 expression as determined by
immunohistochemistry (IHC) was shown to predict for
lower cytogenetic response rate, higher risk for transforma-
tion to sAML and shorter overall survival (OS) in lenalido-
mide-treated MDS patients with del(5q).8 However,
whether p53 expression also influences response to AZA is
unclear. To answer this question, we analyzed the preva-
lence of p53 expression in a cohort of 100 patients with
higher-risk MDS (IPSS intermediate-2 or high), sAML or
MDS/MPN treated with at least one complete cycle of AZA
(75 mg/m²/day for 7 days) and correlated this to outcome. 
Bone marrow (BM) trephine biopsies were obtained
from all patients before the start of AZA. Sections (2 µm)
on SuperFrost microscope slides were de-paraffinized and
pre-treated at 95°C for 7 min in citrate buffer (pH 6). For
quantification and assessment of distribution of progenitor
cells, samples were stained for CD34 (Cellmarque Rocklin,
CA, USA). The DO-7 antibody (DakoCytomation,
Denmark), which labels both wild-type and mutant-type
p53 proteins, was used to detect p53 protein expression.6
The entire trephine section was assessed for p53 protein
nuclear staining in hematopoietic progenitor cells, as previ-
ously described.6-9 In order to minimize the possibility of
false positive results, p53 protein expression was consid-
ered positive only if strong nuclear staining (score 3+) was
present in at least 5% of hematopoietic cells in the entire
BM.6,9 To ensure correct staining, a positive control (urothe-
lial carcinoma) was included on each slide. Molecular TP53
mutation analysis was performed by deep sequencing, as
described previously.2
Patients’ demographic and clinical characteristics are
detailed in Table 1. Thirty-five patients were positive for
p53 expression, 69% of whom had higher-risk MDS (Table
1). In sAML, patients lacking p53 expression were signifi-
cantly more frequent (46%) than p53-positive patients
(26%) (P=0.046). Cytogenetics were scored according to
IPSS-R.10 P53 positive patients were predominantly found
in the very poor risk group (60% p53-positive vs. 14% p53-
negative; P<0.001) (Table 1) and 74% had involvement of
chromosome 5 aberrations. Five patients showed an isolat-
ed del(5q) aberration and TP53 mutations were found in 2
of these (40%). The majority of patients with monosomal
karyotypes were also p53-positive (78%; P<0.001).11 The
chance of exhibiting strong p53 expression was significant-
ly increased in patients with very poor risk cytogenetics
(Odds Ratio (OR): 9.333; 95%CI: 3.517; 24.771; P<0.001)
and with chromosome 5 aberrations (OR: 7.364; 95%CI:
2.886; 18.791; P<0.001) as assessed by univariate binary
logistic regression. In multivariable logistic regression
analysis, a significantly increased chance of p53 expression
was seen only for patients with very poor risk cytogenetics
(OR: 1.488; 95%CI: 1.115; 1.986; P=0.007). 
The overall response rate (ORR) to AZA was assessed
according to IWG 2006 criteria.12 Complete remission in the
bone marrow (BM-CR) without improvement of peripheral
blood values and stable disease without hematologic
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Table 1. Patients’ demographic and clinical characteristics.
N                                        p53 negative      p53 positive             P
                                              patients              patients
                                              (n = 65)              (n = 35)
Age, years                                  71 (55-87)              71 (47-86)
Median (range)                                                                  
MDS (WHO 2008)                     29 (45%)                24 (69%)
RCMD                                            0 (0%)                    3 (9%)
RAEB-1                                           4 (6%)                   4 (11%)                      
RAEB-2                                         25 (39%)                17 (49%)
MDS/MPN (WHO 2008)             6 (9%)                   2 (6%)
sAML (WHO 2008)                    30 (46%)                9 (26%)               0.046†
IPSS
Intermediate-2                          18 (28%)                13 (37%)                     
High                                              14 (22%)                11 (31%) 
Not assessable                         33 (51%)               11 (31%)                     
Cytogenetics (IPSS-R)
Very good                                      1 (2%)                   0 (0%)               <0.001†1
Good                                            29 (45%)                 8 (23%)
Intermediate                              14 (22%)                  1 (3%)
Poor                                              12 (19%)                 5 (14%)
Very poor                                     9 (14%)                 21 (60%)             <0.001*
Very poor cytogenetics
with abnormal Chr. 5              6/23 (26%)            17/23 (74%)           <0.001* 
with monosomal KT              4/18 (22%)          14/18 (78%)          <0.001*
Allogeneic HSCT                       7 (11%)                5 (15%)
For comparison between patients with and without TP53 mutations a Fisher’s exact
(*), c2 (†) or Mann-Whitney-U test (‡) was used. 1c2 test for the difference in very
good to intermediate cytogenetics. 
Table 2. Response to azacitidine.
N p53 negative p53 positive P
patients patients
5-Aza cycles 
Median (range) 4 (1-29) 5 (1-22) 0.926‡
All n=65 n=35
ORR (CR, PR, SD with HI) 16 (25%) 16 (46%) 0.033*
SD without HI 23/32 (72%) 9/32 (28%) 0.020*
MDS n=29 n=24
ORR (CR, PR, SD with HI) 4 (14%) 11 (46%) 0.008*
sAML n=30 n=9 
ORR (CR, PR, SD with HI) 11 (37%) 3 (33%) 
Very poor cytogenetics 
ORR (CR, PR, SD with HI) 3/9 (33%) 7/21 (33%)
+ abnormal Chr. 5 2/6 (33%) 7/17 (41%)
+ monosomal KT 1/4 (25%) 5/14 (36%)
For comparison between patients with and without TP53 mutations a Fisher’s exact
(*), c2 (+) or Mann-Whitney-U test (‡) was used. ORR: overall response rate; CR:
complete remission; PR: partial remission; SD: stable disease; HI: hematologic
improvement.
improvement (HI) were not included in the calculation of
ORR. The ORR for the total cohort was 46% for p53-pos-
itive patients and 25% for p53-negative patients (P=0.033)
(Table 2). The number of AZA cycles administered was
similar in both cohorts. Of note, MDS patients with strong
p53 expression showed a significantly higher ORR than
p53 negative patients (46% vs. 14%; P=0.008).
Interestingly, there was no significant difference in ORR to
AZA in sAML patients according to p53 status (33% ORR
for p53-positive and 37% ORR for p53-negative patients).
In terms of cytogenetic risk, the subgroup of patients with
very poor risk cytogenetics and strong p53 expression
responded as well as patients without p53 expression to
treatment with AZA (33% vs. 33%, respectively). There
appeared to be a better ORR in patients with very poor risk
cytogenetics, chromosome 5 aberation and p53 expression
than in similar patients without p53 expression (ORR 41%
vs. 33%, respectively). A potentially greater ORR also
appeared to be seen in patients with very poor risk cytoge-
netics, monosomal karyotype and p53 expression than in
similar patients without p53 expression (ORR 36% vs.
25%, respectively). However, both subgroups were too
small to reach statistical significance. Interestingly, the con-
siderable subgroup of patients achieving stable disease
without HI (n=32) consisted mainly of p53-negative
patients (72% vs. 28%; P=0.020). Given the retrospective
nature of the analysis, and the fact that patients were not
part of a clinical trial, there was no regular response assess-
ment during follow up. 
Overall survival was measured beginning from start of
AZA. Patients who underwent allogeneic HSCT were cen-
sored at the day of transplantation. The median OS of our
total cohort was 380 days (95%CI: 217; 543), with 246
days (95%CI: 62; 430) for p53-positive patients and 410
days (95%CI: 272; 548) for p53-negative patients (P=NS),
confirming the very poor survival for p53-positive patients
despite response to AZA.1,5-7 A limitation of our study is
that we were not able to evaluate response duration. Of
note, compared to the randomized trial of higher-risk MDS
patients treated with AZA, the ORR in our cohort was
lower.13 This is most likely due to the fact that our patients
were older and included a higher percentage of complex
karyotypes (33% poor or very poor karyotype in our p53-
negative group, 74% poor or very poor karyotype in our
p53-positive group compared to 28% poor risk karyotype
in the AZA-001 trial). Although patients in our cohort with
p53 positivity responded to AZA, response duration may
be shorter than for p53-negative patients; one probable rea-
son for the observed poor overall survival. 
To validate the quality of p53 IHC to detect TP53 muta-
tions, we performed TP53 sequencing of 37 randomly
selected BM samples. TP53 sequencing revealed mutations
in 14 of 37 samples and p53 IHC was positive in 10 of 37
samples. Substantial agreement (Cohens Kappa=0.645;
P<0.001) was seen between both methods. Analysis of the
four TP53mutations not detected by p53 IHC showed two
non-functional mutations: one frameshift and one non-
sense mutation (Table 3). Frameshift and nonsense muta-
tions represent approximately 6-10% and 3-8% of TP53
mutations, respectively.6,14 Regarding the value of TP53
sequencing in relation to IHC for p53 expression, it is
worth noting that sequencing data do not always directly
reflect p53 function since not all TP53 mutations lead to
loss of p53 function. In contrast, strong p53 expression is
an indicator of loss of p53 function due to impairment of
the auto-regulatory feedback loop inducing p53 degrada-
tion. Finally, IHC for p53 expression has recently been
extensively validated for MDS and can thus be considered
a reliable method to assess for dysfunctional TP53.6,7,8
In summary, we show in a large cohort of 100 patients
with higher-risk MDS and sAML treated with AZA that
p53 expression as a surrogate for the presence of TP53
mutations does not negatively impact on treatment
response. Accordingly, the combination of AZA and
lenalidomide may confer a benefit in higher-risk MDS
patients with del(5q) harboring TP53mutations and should
be assessed in future trials.15
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